Preferential humoral immune response in prostate cancer to cellular proteins p90 and p62 in a panel of tumor-associated antigens.
about
CIP2A expression is increased in prostate cancerThe Present and Future of Biomarkers in Prostate Cancer: Proteomics, Genomics, and Immunology AdvancementsIdentification of an autoantibody panel to separate lung cancer from smokers and nonsmokersPreferential autoimmune response in prostate cancer to cyclin B1 in a panel of tumor-associated antigensDetection of autoantibodies to multiple tumor-associated antigens in the immunodiagnosis of ovarian cancer.A novel multiplex assay combining autoantibodies plus PSA has potential implications for classification of prostate cancer from non-malignant cases.Autoantibodies to tumor-associated antigens as biomarkers in cancer immunodiagnosis.Loss of exon identity is a common mechanism of human inherited disease.Tumor-associated antigen arrays for the serological diagnosis of cancer.Mini-array of multiple tumor-associated antigens to enhance autoantibody detection for immunodiagnosis of hepatocellular carcinoma.Ets1 and Elk1 transcription factors regulate cancerous inhibitor of protein phosphatase 2A expression in cervical and endometrial carcinoma cells.Tumor suppressor miR-375 regulates MYC expression via repression of CIP2A coding sequence through multiple miRNA-mRNA interactions.Autoantibodies to tumor-associated antigens: reporters from the immune system.Serum anti-CCNY autoantibody is an independent prognosis indicator for postoperative patients with early-stage nonsmall-cell lung carcinomaUsing immunoproteomics to identify tumor-associated antigens (TAAs) as biomarkers in cancer immunodiagnosis.Antibody detection using tumor-associated antigen mini-array in immunodiagnosing human hepatocellular carcinoma.A systematic review of humoral immune responses against tumor antigens.Evaluation and characterization of anti-RalA autoantibody as a potential serum biomarker in human prostate cancer.Identifying autoantibody signatures in cancer: a promising challenge.Serum autoantibodies as biomarkers for early cancer detection.Autoantibodies against oncogenic ERG protein in prostate cancer: potential use in diagnosis and prognosis in a panel with C-MYC, AMACR and HERV-K Gag.The cyclins: a family of widely expressed tumor antigens?Identification of the transcription factor single-minded homologue 2 as a potential biomarker and immunotherapy target in prostate cancer.Using Serological Proteome Analysis to Identify Serum Anti-Nucleophosmin 1 Autoantibody as a Potential Biomarker in European-American and African-American Patients With Prostate Cancer.Osteopontin is a tumor autoantigen in prostate cancer patients.Autoantibody detection to tumor-associated antigens of P53, IMP1, P16, cyclin B1, P62, C-myc, Survivn, and Koc for the screening of high-risk subjects and early detection of esophageal squamous cell carcinoma.Optimizing peptide epitope-based autoantibody detection in cancer patients.Dr Eng M. Tan: a tribute to an enduring legacy in autoimmunity.
P2860
Q21198842-48AEEED9-4963-4C3D-B931-2D651943E18AQ26750672-AF980B78-CEB4-424D-A1BD-D619A89D842FQ33588113-03B8DE45-41E5-4521-8524-D5416037BC2CQ33594076-DEF90FD6-E2C2-4923-82A0-CEAE06BFB2D8Q33890172-134CC9CD-578C-4D00-AE72-D3F62757486EQ35009135-6D1F246E-D6B1-47D9-8DE4-F558CD7B022AQ35059164-1C6729F9-B810-4250-BD45-9C29FC9AF0D4Q35451644-9CF8B548-2DFF-4DA6-972C-ADBBFD772817Q36491988-736E49C1-80BA-4942-A21E-2C9C7388A432Q36731844-F880097E-3B51-4590-8C94-45F5FACB29A0Q36777896-2CFEEB3D-6E64-408D-843B-B498BF5C279AQ36887378-1F4DB57F-2EBA-4365-9719-5086BA2E50E9Q37118192-9F23174D-3C08-4B41-A682-433EC0B0DA52Q37212230-418160D2-3AE6-42FE-B4BD-890341D4BEAEQ37213540-80E4419B-30CD-41AD-B8DC-DC7042CE2F67Q37252915-DFF139CA-0B1A-47E7-B678-50C2FEE3544CQ37435862-568452B5-907A-4E00-8761-97E21F84633FQ37536632-5AB9004B-7224-4D81-B7D7-7083575C0E7EQ37579900-A5A7A861-625D-4CE9-9544-71ACF1F43D1CQ37622471-3294358A-862F-4A94-BEB9-5F9BEBA40930Q37635618-58A5F75C-E8AB-4528-94B7-1C1DF78E103DQ37857261-603EDABE-642D-4AEF-A48E-E2BDD4AF1A3DQ38350670-0648404B-CFEC-4CA0-9B5A-B6AF9582E682Q38758065-DD24BE53-60A6-4B7C-AE18-9EC2F4FEDD2DQ41810965-D1FE366E-E8F1-4DFF-9B91-07C46CE11202Q42447000-7CB11D4B-1080-4678-8E68-CDCA86E65DFBQ46190333-DE656D16-D496-4B3C-A971-63D0E5F73BD4Q47187009-9DD82F37-436F-4F5F-8FB5-BDFD0A5CEBA9
P2860
Preferential humoral immune response in prostate cancer to cellular proteins p90 and p62 in a panel of tumor-associated antigens.
description
2005 nî lūn-bûn
@nan
2005 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Preferential humoral immune re ...... of tumor-associated antigens.
@ast
Preferential humoral immune re ...... of tumor-associated antigens.
@en
type
label
Preferential humoral immune re ...... of tumor-associated antigens.
@ast
Preferential humoral immune re ...... of tumor-associated antigens.
@en
prefLabel
Preferential humoral immune re ...... of tumor-associated antigens.
@ast
Preferential humoral immune re ...... of tumor-associated antigens.
@en
P2093
P356
P1433
P1476
Preferential humoral immune re ...... l of tumor-associated antigens
@en
P2093
Ann Rearden
Carlos A Casiano
Dan Nachtsheim
Daorong Liu
Fu-Dong Shi
Jian-Ying Zhang
Mary Jo Heeb
Max Elliot
Tracy Daniels
P2860
P304
P356
10.1002/PROS.20181
P50
P577
2005-05-01T00:00:00Z